EFTR
vs
S&P 500
EFTR
S&P 500
Over the past 12 months, EFTR has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +14% growth.
Stocks Performance
EFTR vs S&P 500
Performance Gap
EFTR vs S&P 500
Performance By Year
EFTR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
eFFECTOR Therapeutics Inc
Glance View
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). The company is headquartered in Solana Beach, California and currently employs 13 full-time employees. The company went IPO on 2021-01-08. The firm is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The company uses selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The firm's lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an inhibitor of programed cell death protein 1 (PD-1) in a randomized Phase IIb clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase I/II clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.
